To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Pain
Tuesday 26th January 2016

Asked by: Mark Durkan (Social Democratic & Labour Party - Foyle)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, with reference to the Royal College of Anaesthetists' report entitled, Core Standards for Pain Management Services in the UK, published in October 2015, whether his Department has given any consideration to the contents of that report.

Answered by Jane Ellison

NHS England has welcomed the publication of the Core Standards for Pain Management report in the United Kingdom, published by the Faculty of Pain Medicine of the Royal College of Anaesthetists in October 2015. Andrew Baranowski, the Chair of NHS England’s Clinical Reference Group for Specialised Pain contributed to this work, which sets out core standards and key recommendations in the management of pain; the commissioning of pain management services and the development of the workforce.


The report is available at:


http://www.rcoa.ac.uk/system/files/FPM-CSPMS-UK2015.pdf



Written Question
Cancer: Drugs
Friday 22nd January 2016

Asked by: Mark Durkan (Social Democratic & Labour Party - Foyle)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, if he will ask NHS England to publish a case study of the revised Cancer Drugs Fund (CDF) patient journey and give examples for how people are initiated onto CDF-approved treatments now and how people will be treated under the proposed new CDF scheme.

Answered by George Freeman

NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation document states that all patients receiving treatment funded through the CDF on 31 March 2016 will continue to receive treatment until the point that they and their consultant agree that it is appropriate to stop.


NHS England has advised that the aim of the future CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the National Health Service in the future. It is not possible to make comparisons between the current and future CDF until such time as the consultation has concluded and the responses reviewed.


The consultation was published on 19 November 2015 and is open until 11 February 2016. Further information is available at:


www.engage.england.nhs.uk/consultation/cdf-consultation


Written Question
Cancer: Drugs
Friday 22nd January 2016

Asked by: Mark Durkan (Social Democratic & Labour Party - Foyle)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what discussions the his Department, NHS England and NICE have had on the effect of proposed Cancer Drugs Fund (CDF) changes on patients prescribed current CDF treatments who will not receive interim funding under that proposed new scheme.

Answered by George Freeman

NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation document states that all patients receiving treatment funded through the CDF on 31 March 2016 will continue to receive treatment until the point that they and their consultant agree that it is appropriate to stop.


NHS England has advised that the aim of the future CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the National Health Service in the future. It is not possible to make comparisons between the current and future CDF until such time as the consultation has concluded and the responses reviewed.


The consultation was published on 19 November 2015 and is open until 11 February 2016. Further information is available at:


www.engage.england.nhs.uk/consultation/cdf-consultation


Speech in Commons Chamber - Thu 21 Jan 2016
Infected Blood

"I welcome the statement and commend the shadow Minister’s tone. Victims in Northern Ireland share the compound frustration that we have heard from other Members on behalf of their constituents, but maybe feel more pointedly the contrast with their friends in the south of Ireland, who have had a path …..."
Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: Infected Blood

Speech in Westminster Hall - Mon 11 Jan 2016
NHS Bursary

"It is a pleasure to take part in this important debate. I commend the hon. Member for Sutton and Cheam (Paul Scully) for introducing it as a Petitions Committee member. He had the difficult task of framing the wider debate by drawing attention to a number of the background and …..."
Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: NHS Bursary

Speech in Westminster Hall - Mon 11 Jan 2016
NHS Bursary

"I take the hon. Gentleman’s point, which resets the context of his comments. I gladly acknowledge that clarification.

Just as we should not presume that bursaries are a given and cannot be taken away, people cannot afford to presume that the assurances about the loans-based policy are a given. The …..."

Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: NHS Bursary

Speech in Westminster Hall - Mon 11 Jan 2016
NHS Bursary

"The Minister has criticised colleagues several times during the debate and said that the Government are not hearing alternatives. Will he reframe the consultation so that they can hear alternatives? It is clear that people want to work on a different premise and to a different agenda, with much better …..."
Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: NHS Bursary

Written Question
Cancer: Mortality Rates
Tuesday 5th January 2016

Asked by: Mark Durkan (Social Democratic & Labour Party - Foyle)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what steps he is taking to improve one-year cancer survival rates over the next five years.

Answered by Jane Ellison

We want to lead the world in fighting cancer. Survival rates have never been higher, but we want to go further. In England, the independent Cancer Taskforce’s five-year strategy for cancer, Achieving World-Class Cancer Outcomes, published in July 2015, recommends improvements across the cancer pathway with the aim of improving survival rates.


Updated National Institute for Health and Care Excellence referral guidelines for suspected cancer could save about 5,000 lives with general practitioners urged to think of cancer sooner and lower the referral threshold for tests. Whilst health is, of course, a devolved matter, we know that these guidelines are often used by the devolved administrations.


Speech in Commons Chamber - Thu 17 Dec 2015
Conception to Age 2: The First 1001 Days

"It is a pleasure to follow the right hon. Member for North Norfolk (Norman Lamb), who touched strongly on perinatal mental health. That is one of the issues addressed in the work of the all-party parliamentary group on conception to age two—the first 1001 days. In common with others, I …..."
Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: Conception to Age 2: The First 1001 Days

Speech in Commons Chamber - Wed 16 Dec 2015
Victims of Contaminated Blood: Support

"The Minister may recall that when the all-party group met her in early November we warned her that any slippage would be greeted as slipperiness by people who had suffered delays for too long. Does she appreciate that people will worry about the possibility that the extra time has been …..."
Mark Durkan - View Speech

View all Mark Durkan (SDLP - Foyle) contributions to the debate on: Victims of Contaminated Blood: Support